Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer

Pietro de Besi, Luigi Salvagno, Luigi Endrizzi, Vanna Chiarion Sileni, Vinicio Fosser, Giuseppe Cartei, Adriano Paccagnella, Eduardo Leon Pardo, Carlo Tremolada, Alberto Peracchia, Mario V. Fiorentino

Research output: Contribution to journalArticlepeer-review


From February 1981 to September 1982, 34 patients with metastatic or locally advanced (inoperable) epidermoid carcinoma of the oesophagus were treated with a combination of cisplatin, bleomycin and methotrexate. Thirty-one patients are now evaluable for response: 16 of 31 (52%) experienced some improvement, but only eight (26%) obtained major responses (one complete and seven partial). Responses were obtained rapidly within the first two courses. The median duration of responses was 5 months. The median survival from start of therapy was 8 months for responsive and 5 months for non-responsive patients. Gastrointestinal toxicity (cisplatin-related) and mild myelosuppression were the most prominent side-effects. This combination chemotherapy proved to be only of small efficacy in the long-term control of advanced oesophageal cancer. However, because the responses were obtained rapidly, it is conceivable that a similar regimen (with increased dosage of cisplatin) applied before surgery to patients with limited disease could obtain a reduction of the bulky tumour, with a possible increase of the resectability rate and destruction of micrometastases.

Original languageEnglish
Pages (from-to)743-747
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number6
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer'. Together they form a unique fingerprint.

Cite this